Purdue's reformulated OxyContin gets US panel backing on second try
This article was originally published in Scrip
Purdue Pharma's reformulated OxyContin (oxycodone extended-release) may be less susceptible to abuse and manipulation than the currently marketed version, but risk management plans and postmarketing studies will be critical to determining whether the formulation is actually safer, the US FDA's outside experts have said.
You may also be interested in...
US FDA expects to receive two more postmarket studies this year, but Purdue has not yet decided if it will resubmit a supplemental NDA. Consortium of 13 companies have completed six additional studies on extended-release opioids.
Oncologic Drugs Advisory Committee asked to weigh in on adequacy of GSK’s proposal for two single-arm trials to support accelerated approval in a curative setting, as well as the potential novel use of clinical complete response as an approval endpoint.
Aduhelm Shows Need For More FDA Transparency On Approval Decisions, Surrogate Endpoints, Critics Say
But Center for Drug Evaluation and Research leaders stand their ground at a National Academies meeting, asserting the Phase III data for a different Alzheimer’s drug, Leqembi, are likely to confirm their views on utility of amyloid as a surrogate endpoint.